REPAGLINIDE AND METFORMIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Repaglinide And Metformin Hydrochloride patents expire, and when can generic versions of Repaglinide And Metformin Hydrochloride launch?
Repaglinide And Metformin Hydrochloride is a drug marketed by Lupin Ltd and is included in one NDA.
The generic ingredient in REPAGLINIDE AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; repaglinide. There are forty-nine drug master file entries for this compound. Additional details are available on the metformin hydrochloride; repaglinide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REPAGLINIDE AND METFORMIN HYDROCHLORIDE?
- What are the global sales for REPAGLINIDE AND METFORMIN HYDROCHLORIDE?
- What is Average Wholesale Price for REPAGLINIDE AND METFORMIN HYDROCHLORIDE?
Summary for REPAGLINIDE AND METFORMIN HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 22 |
| DailyMed Link: | REPAGLINIDE AND METFORMIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for REPAGLINIDE AND METFORMIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medicines for Malaria Venture | Phase 1 |
| Novartis Pharmaceuticals | Phase 1 |
| AstraZeneca | Phase 2/Phase 3 |
See all REPAGLINIDE AND METFORMIN HYDROCHLORIDE clinical trials
US Patents and Regulatory Information for REPAGLINIDE AND METFORMIN HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | REPAGLINIDE AND METFORMIN HYDROCHLORIDE | metformin hydrochloride; repaglinide | TABLET;ORAL | 200624-001 | Jul 15, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin Ltd | REPAGLINIDE AND METFORMIN HYDROCHLORIDE | metformin hydrochloride; repaglinide | TABLET;ORAL | 200624-002 | Jul 15, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
